Goldstein Dan 4
4 · HAEMONETICS CORP · Filed Feb 5, 2021
Insider Transaction Report
Form 4
Goldstein Dan
Chief Accounting Officer
Transactions
- Sale
Common Stock
2021-02-04$135.88/sh−476$64,679→ 1,749 total - Exercise/Conversion
Common Stock
2021-02-04$98.03/sh+500$49,013→ 2,249 total - Sale
Common Stock
2021-02-04$135.72/sh−500$67,860→ 1,749 total - Sale
Common Stock
2021-02-04$136.26/sh−238$32,430→ 1,511 total - Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2021-02-04−1,457→ 0 totalExercise: $34.21From: 2017-10-25Exp: 2023-10-25→ Common Stock (1,457 underlying) - Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2021-02-04−476→ 952 totalExercise: $93.52From: 2019-06-11Exp: 2025-06-11→ Common Stock (476 underlying) - Exercise/Conversion
Common Stock
2021-02-04$34.21/sh+1,457$49,844→ 3,206 total - Sale
Common Stock
2021-02-04$135.84/sh−1,457$197,919→ 1,749 total - Exercise/Conversion
Common Stock
2021-02-04$93.52/sh+476$44,516→ 2,225 total - Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2021-02-04−500→ 1,503 totalExercise: $98.03From: 2020-05-14Exp: 2026-05-14→ Common Stock (500 underlying)
Footnotes (2)
- [F1]This number includes unvested restricted stock units previously reported.
- [F2]Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.